http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AT-514002-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 |
| filingDate | 2012-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AT-514002-A2 |
| titleOfInvention | Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV) |
| abstract | The invention relates to a combination of at least two direct-acting antiviral agents (DAAs) for use in the treatment of HCV, the at least two DAAs comprising PSI-7977 and GS-5885, or PSI-7977 and an HCV NS5A inhibitor, and the treatment includes neither the administration of interferon nor ribavirin, and wherein the treatment is for 8, 9, 10, 11, or 12 weeks, and the treatment is for a patient infected with HCV genotype 1. |
| priorityDate | 2011-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 406.